Artelo updates ATM to $3,451,527 stock offering

Artelo Biosciences is updating its at-the-market offering to cover up to $3,451,527 of common stock under its existing Sales Agreement with R.F.

Rhea-AI Filing Summary

Artelo Biosciences is updating its at-the-market offering to cover up to $3,451,527 of common stock under its existing Sales Agreement with R.F. Lafferty & Co., Inc.

This reduces the prior at-the-market capacity from $6,500,000, and the new cap includes approximately $451,526.95 of common stock already sold under the program. The amendment keeps all other terms of the at-the-market facility and the Sales Agreement unchanged.

The company also notes a public float of $22,062,306 as of a recent date, based on 777,881 shares outstanding and a $28.50 Nasdaq closing price on July 10, 2025, and confirms it will not sell more than one-third of this public float in any 12-month period while the float remains below $75,000,000.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change is Artelo Biosciences (ARTL) making to its at-the-market offering?

Artelo Biosciences is reducing the maximum aggregate gross sales price of common stock it may offer and sell under its at-the-market program to $3,451,527, including shares previously sold.

How large was Artelo Biosciences' prior at-the-market capacity before this supplement?

Before this supplement, Artelo's at-the-market program allowed for the offer and sale of up to $6,500,000 of common stock under the Sales Agreement.

How much common stock has Artelo Biosciences already sold under the ATM program?

As of the date of this prospectus supplement, Artelo reports it has sold $451,526.95 of common stock covered by the at-the-market prospectus.

What is Artelo Biosciences' public float referenced in this ATM update?

Artelo states that the aggregate market value of its common stock held by non-affiliates is $22,062,306, based on 774,116 non-affiliate shares and a $28.50 Nasdaq closing price on July 10, 2025.

What limitation applies to Artelo (ARTL) ATM sales under Form S-3 Instruction I.B.6?

Artelo states that, under General Instruction I.B.6 of Form S-3, it will not sell shares under this prospectus supplement with a value exceeding more than one-third of its public float in any 12-month period while its public float remains below $75,000,000.

Does this prospectus supplement change Artelo's Sales Agreement with R.F. Lafferty?

No. Artelo confirms that, aside from reducing the at-the-market size, the terms of the offering remain unchanged and the Sales Agreement with R.F. Lafferty & Co., Inc. remains in full force and effect.

On which exchange is Artelo Biosciences (ARTL) common stock listed and what was a recent price?

Artelo's common stock is listed on The Nasdaq Capital Market under the symbol ARTL, and the last reported sale price on Nasdaq as of September 3, 2025, was $8.76 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 07:24 AM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-273153

PROSPECTUS SUPPLEMENT

(To Prospectus dated July 14, 2023)

Up to $3,451,527

Shares of Common Stock 

This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025 (the “ATM Prospectus”), relating to the offer and sale of up to $6,500,000  shares of our common stock, $0.001 par value per share (“Common Stock”), pursuant to the At the Market Offering Agreement between us and R.F. Lafferty & Co., Inc., as exclusive sales agent (who we refer to herein as “Lafferty” or the “Sales Agent”), dated July 18, 2025 (the “Sales Agreement”). This prospectus supplement should be read in conjunction with the ATM Prospectus and the base prospectus, dated July 7, 2023 (the “Base Prospectus”), and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus or the Base Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with the ATM Prospectus and the Base Prospectus and any future amendments or supplements thereto.

The Common Stock is listed on The Nasdaq Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ARTL.” As of September 3, 2025, the last reported sales price of the Common Stock on Nasdaq was $8.76.

We are filing this prospectus supplement to supplement and amend, as of September 4, 2025, the ATM Prospectus and the Base Prospectus, to reduce the maximum aggregate gross sales price of our Common Stock that may be offered, issued and sold under the Sales Agreement from and after the date hereof to $3,451,527 (the “ATM Offering Size Reduction”), including the Common Stock previously sold. Under the ATM Prospectus, we initially registered up to $6,500,000 of our Common Stock for offer and sale pursuant to the Sales Agreement. As of the date of the filing of this prospectus supplement, we have sold $451,526.95 shares of Common Stock that are covered by the ATM Prospectus.

The purpose of this prospectus supplement is to update the ATM Prospectus to reflect the ATM Offering Size Reduction. Except as modified by this prospectus supplement, the terms of the ATM offering remain unchanged, and the Sales Agreement remains in full force and effect.

The aggregate market value of our outstanding shares of Common Stock held by non-affiliates as of September 3, 2025, is $22,062,306, based on 777,881 shares of Common Stock outstanding, of which 774,116 are held by non-affiliates, and a closing price on Nasdaq of $28.50 on July 10, 2025, which is within 60 days of the date of this prospectus supplement. Upon any sale of shares of Common Stock under this prospectus supplement pursuant to General Instruction I.B.6. of Form S-3, in no event will we sell shares pursuant to this prospectus supplement having a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000.

Investing in our shares of Common Stock involves a high degree of risk and uncertainty. See “Risk Factors” beginning on page S-9 of the ATM Prospectus and the other documents that are incorporated by reference in the ATM Prospectus and the accompanying base prospectus.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT, THE PRIOR PROSPECTUS SUPPLEMENTS OR THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

R.F. Lafferty & Co., Inc.

______________

The date of this prospectus supplement is September 4, 2025.